Xiaofen Li

3.1k total citations · 1 hit paper
106 papers, 2.1k citations indexed

About

Xiaofen Li is a scholar working on Oncology, Surgery and Pathology and Forensic Medicine. According to data from OpenAlex, Xiaofen Li has authored 106 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 18 papers in Surgery and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Xiaofen Li's work include Pancreatic and Hepatic Oncology Research (11 papers), Neuroendocrine Tumor Research Advances (8 papers) and Genetic factors in colorectal cancer (8 papers). Xiaofen Li is often cited by papers focused on Pancreatic and Hepatic Oncology Research (11 papers), Neuroendocrine Tumor Research Advances (8 papers) and Genetic factors in colorectal cancer (8 papers). Xiaofen Li collaborates with scholars based in China, United States and Australia. Xiaofen Li's co-authors include Bing Fan, Zicong Li, Bingliang Zeng, Honglu Li, Chuanhong Wang, Qinglin Shen, Hongbiao Huang, Ningning Liu, Shouting Liu and Jinbao Liu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Xiaofen Li

96 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?

2020 646 citations Xiaofen Li et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaofen Li China	22	516	488	452	354	267	106	2.1k
David A. Drew United States	20	672 1.3×	835 1.7×	150 0.3×	448 1.3×	309 1.2×	62	2.9k
Meifang Wang China	21	383 0.7×	505 1.0×	205 0.5×	955 2.7×	419 1.6×	79	2.4k
Hong Ma China	27	589 1.1×	960 2.0×	181 0.4×	284 0.8×	293 1.1×	160	2.6k
Xiaomeng Zhang China	22	199 0.4×	352 0.7×	150 0.3×	205 0.6×	272 1.0×	106	1.7k
Jiannan Feng China	24	531 1.0×	1.1k 2.2×	488 1.1×	1.2k 3.4×	119 0.4×	137	3.4k
Dario Bruzzese Italy	33	337 0.7×	459 0.9×	186 0.4×	216 0.6×	783 2.9×	177	3.3k
Qing Gong China	15	538 1.0×	517 1.1×	140 0.3×	872 2.5×	185 0.7×	40	3.4k
Koichi Yuki United States	29	235 0.5×	854 1.8×	210 0.5×	816 2.3×	559 2.1×	139	4.0k
Ying Yan China	22	275 0.5×	424 0.9×	173 0.4×	545 1.5×	126 0.5×	106	2.2k
Li Niu China	16	335 0.6×	266 0.5×	249 0.6×	1.2k 3.5×	322 1.2×	43	2.2k

Countries citing papers authored by Xiaofen Li

Since Specialization

Citations

This map shows the geographic impact of Xiaofen Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaofen Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaofen Li more than expected).

Fields of papers citing papers by Xiaofen Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaofen Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaofen Li. The network helps show where Xiaofen Li may publish in the future.

Co-authorship network of co-authors of Xiaofen Li

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaofen Li. A scholar is included among the top collaborators of Xiaofen Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaofen Li. Xiaofen Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Xiaofen, et al.. (2025). The Impact of Post Mastectomy Radiotherapy on T1-2N0-1 Male Breast Cancer and establishment of an artificial neural network predicting model: Population-Based Study. Cancer Research and Treatment.

Hu, Beilei, Qing Guo, Xiaofen Li, et al.. (2024). Escitalopram moderately outperforms citalopram towards anti-neuroinflammation and neuroprotection in 6-hydroxydopamine-induced mouse model of Parkinson’s disease. International Immunopharmacology. 139. 112715–112715. 2 indexed citations

Li, Xiaofen, Xin You, Minggang Su, et al.. (2024). Surufatinib combined with transarterial embolization versus surufatinib monotherapy in patients with liver metastatic neuroendocrine tumors: Study protocol for a prospective, randomized, controlled trial. Cancer Medicine. 13(8). e7131–e7131. 1 indexed citations

Wang, Qing, Chenxi Wang, Jialu Li, et al.. (2024). Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer. British Journal of Cancer. 132(3). 295–310. 4 indexed citations

Li, Xiaofen, et al.. (2023). Prediction of Chemotherapy Efficacy in Patients with Colorectal Cancer Ovarian Metastases: A Preliminary Study Using Contrast-Enhanced Computed-Tomography-Based Radiomics. Diagnostics. 14(1). 6–6. 1 indexed citations

Liang, Yun, Meng Ma, Dickson Adah, et al.. (2023). Plasmodium immunotherapy combined with gemcitabine has a synergistic inhibitory effect on tumor growth and metastasis in murine Lewis lung cancer models. Frontiers in Oncology. 13. 1181176–1181176. 6 indexed citations

Li, Xiaofen, Chao Fang, Xin Wang, et al.. (2022). Neoadjuvant treatment of sintilimab plus hypofractionated radiotherapy for MSI‐H/dMMR rectal cancer: A prospective, multicenter, phase Ib study. Cancer Medicine. 11(23). 4405–4410. 6 indexed citations

Cheng, Ke, et al.. (2022). Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer. Frontiers in Oncology. 11. 759652–759652. 5 indexed citations

Li, Xiaofen, Limin Gao, Meng Qiu, & Dan Cao. (2021). Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation. OncoTargets and Therapy. Volume 14. 2815–2819. 2 indexed citations

10.

Wei, Xiaoli, Qianwen Liu, Furong Liu, et al.. (2021). The clinicopathological significance and predictive value for immunotherapy of programmed death ligand-1 expression in Epstein-Barr virus-associated gastric cancer. OncoImmunology. 10(1). 1938381–1938381. 17 indexed citations

11.

Chang, Chen, Xiaofen Li, & Dan Cao. (2021). Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study. BMC Cancer. 21(1). 545–545. 4 indexed citations

12.

Li, Xiaofen, et al.. (2021). The efficacy of aprepitant in salvage treatment of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy for patients with gastrointestinal cancer. International Journal of Clinical Oncology. 26(6). 1091–1098.

13.

Li, Xiaofen, et al.. (2020). <p>Impact of Ovarian Metastatectomy on Survival Outcome of Colorectal Cancer Patients with Ovarian Metastasis: A Retrospective Study</p>. Cancer Management and Research. Volume 12. 4493–4501. 9 indexed citations

14.

Li, Xiaofen, et al.. (2020). Third-line sunitinib treatment in a VHL-mutated metastatic intrahepatic cholangiocarcinoma: a case report and literature review. Cancer Biology & Therapy. 21(9). 785–789. 2 indexed citations

15.

Meyers, Marvin J., Zhijun Liu, Hongwei Ma, et al.. (2019). 4-Aryl Pyrrolidines as Novel Orally Efficacious Antimalarial Agents. Part 2: 2-Aryl-N-(4-arylpyrrolidin-3-yl)acetamides. ACS Medicinal Chemistry Letters. 10(6). 966–971. 5 indexed citations

16.

Hu, Wangxiong, Yanmei Yang, Xiaofen Li, et al.. (2018). Multi-omics Approach Reveals Distinct Differences in Left- and Right-Sided Colon Cancer. Molecular Cancer Research. 16(3). 476–485. 40 indexed citations

17.

Li, Xiaofen, Ying Yuan, & Suzhan Zhang. (2016). Characteristics and clinical management of Chinese hereditary colorectal cancer syndromes. Zhongguo aizheng zazhi. 25(11). 841–847. 1 indexed citations

18.

Fan, Lihua, et al.. (2015). Effect of preoperative sleep disturbance on efficacy of postoperative analgesia and comfort in patients undergoing colorectal cancer resection surgery. Zhongguo jiceng yiyao. 22(4). 481–483. 1 indexed citations

19.

Li, Xiaofen. (2015). Research progress of Lynch syndrome in China. 4(3). 244–249.

20.

Shi, Xianping, Xin Chen, Xiaofen Li, et al.. (2013). Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation. Clinical Cancer Research. 20(1). 151–163. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact